6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

Change of the switch point between dual-E and single-E control with decreasing values of <i>k</i>₉, <i>k</i>₁₁, and <i>k</i>₁₃. by Qaiser Waheed (5095328)

Strains used in this study. by Xin Zhou (54275)

“…Here, we found that the ergosterol biosynthesis gene <i>ERG251</i> is a hotspot for point mutations during adaptation to antifungal drug stress within two distinct genetic backgrounds of <i>Candida albicans</i>. …”

Primers used in this study. by Xin Zhou (54275)

“…Here, we found that the ergosterol biosynthesis gene <i>ERG251</i> is a hotspot for point mutations during adaptation to antifungal drug stress within two distinct genetic backgrounds of <i>Candida albicans</i>. …”

<i>ERG251</i> SNPs from all FLC-evolved strains. by Xin Zhou (54275)

“…Here, we found that the ergosterol biosynthesis gene <i>ERG251</i> is a hotspot for point mutations during adaptation to antifungal drug stress within two distinct genetic backgrounds of <i>Candida albicans</i>. …”

Serotype-specific penicillin non-susceptibility during different PCV periods in Iceland, Romania, Spain and Belgium [68, 69, 76, 78, 84, 85]. by Heloisa Ricci Conesa (18291210)

Klf5 activates the transcription of the eIF5a gene through direct binding to its promoter. by Dong Ma (584680)

Subjects:

Klf5 and eIF5a suppress Ang II–induced expression of NOX1 in VSMCs. by Dong Ma (584680)

Subjects:

Phlorizin decreased renal GTTR uptake, and increased serum drug levels <i>in vivo</i>. by Meiyan Jiang (438439)

Procedures of sampling and measurements. by Xuegang Mao (599968)

Introduction status of PCVs in European countries over time. by Heloisa Ricci Conesa (18291210)

Erg251 is the major methyl sterol oxidase controlling drug susceptibility compared to its paralog Erg25. by Xin Zhou (54275)

Data extraction grid. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

Incidence rates of AOM cases. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

Inclusion criteria. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

PRISMA flow diagram for the literature search. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

Estimates for direct medical and total costs per AOM episode (2020 EUR), by country [35, 96–100]. by Heloisa Ricci Conesa (18291210)